{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:06:22Z","timestamp":1793325982971,"version":"4.5.0"},"reference-count":171,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Women carrying pathogenic\/likely pathogenic (P\/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P\/LP variants associated with breast cancer risk show incomplete penetrance. Age, gender, family history, polygenic risk, lifestyle, reproductive, hormonal, and environmental factors can affect the expressivity and penetrance of the disease. However, there are gaps in translating how individual genomic variation affects phenotypic presentation. The expansion of criteria for genetic testing and the increasing utilization of comprehensive genetic panels may enhance the identification of individuals carrying P\/LP variants linked to hereditary breast cancer. Individualized risk assessment could facilitate the implementation of personalized risk-reduction strategies for these individuals. Preventive interventions encompass lifestyle modifications, chemoprevention, enhanced surveillance through breast imaging, and risk-reducing surgeries. This review addresses the current literature\u2019s inconsistencies and limitations, particularly regarding risk factors and the intensity of preventive strategies for women with P\/LP variants in moderate- and high-penetrance genes. In addition, it synthesizes the latest evidence on risk assessment and primary and secondary prevention in women at high risk of breast cancer.<\/jats:p>","DOI":"10.3390\/genes16010082","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:49:17Z","timestamp":1736761757000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-091X","authenticated-orcid":false,"given":"Eliza Del Fiol","family":"Manna","sequence":"first","affiliation":[{"name":"Division of Oncogenetics, Unimed Sorocaba, Sorocaba 18040-580, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-4108","authenticated-orcid":false,"given":"Davide","family":"Serrano","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-2852","authenticated-orcid":false,"given":"Laura","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"},{"name":"Department of Health Sciences, Medical Genetics, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zanzottera","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fava","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Aurilio","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-1688","authenticated-orcid":false,"given":"Aliana","family":"Guerrieri-Gonzaga","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-3109","authenticated-orcid":false,"given":"Matilde","family":"Risti","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-8503","authenticated-orcid":false,"given":"Mariarosaria","family":"Calvello","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"},{"name":"Department of Health Sciences, Medical Genetics, University of Milan, 20122 Milan, Italy"},{"name":"Oncology Competence Center, Gruppo Ospedaliero Moncucco, 6900 Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9312-2020","authenticated-orcid":false,"given":"Irene","family":"Feroce","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Marabelli","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4213-7069","authenticated-orcid":false,"given":"Cecilia","family":"Altemura","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-1431","authenticated-orcid":false,"given":"Lucio","family":"Bertario","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-2128","authenticated-orcid":false,"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-4002","authenticated-orcid":false,"given":"Matteo","family":"Lazzeroni","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Velentzis, L.S., Freeman, V., Campbell, D., Hughes, S., Luo, Q., Steinberg, J., Egger, S., Mann, G.B., and Nickson, C. (2023). Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15041124"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). Breast Cancer\u2014Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies\u2014An Updated Review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sardanelli, F., and Podo, F. (2020). Hereditary Breast CancerBreast cancer: BRCA and Other Susceptibility GenesSusceptibility genes. Breast MRI for High-Risk Screening, Springer International Publishing.","DOI":"10.1007\/978-3-030-41207-4"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"National Comprehensive Cancer Network (2024, November 27). Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (Version 2.2025). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.breast.2022.06.003","article-title":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","volume":"65","author":"Graffeo","year":"2022","journal-title":"Breast"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.gde.2010.02.009","article-title":"Discovering moderate-risk breast cancer susceptibility genes","volume":"20","author":"Hollestelle","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"pkab044","DOI":"10.1093\/jncics\/pkab044","article-title":"Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network","volume":"5","author":"Fan","year":"2021","journal-title":"JNCI Cancer Spectr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13053-021-00191-0","article-title":"Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations","volume":"19","author":"Meshkani","year":"2021","journal-title":"Hered. Cancer Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/onc.2015.181","article-title":"Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations","volume":"35","author":"Golmard","year":"2015","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kingdom, R., and Wright, C.F. (2022). Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.920390"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1200\/JCO.2024.42.16_suppl.10596","article-title":"A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic\/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1245\/s10434-017-5963-7","article-title":"Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk","volume":"24","author":"Iacoboni","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bellhouse, S., Hawkes, R.E., Howell, S.J., Gorman, L., and French, D.P. (2021). Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours. Cancers, 13.","DOI":"10.3390\/cancers13164150"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/OP.21.00551","article-title":"Reducing Breast Cancer Incidence and Mortality: Rethinking an Approach to Risk Assessment and Prevention","volume":"17","author":"Pruthi","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation Detection in Patients with Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"Jama"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk","volume":"372","author":"Easton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rolfes, M., Borde, J., M\u00f6llenhoff, K., Kayali, M., Ernst, C., Gehrig, A., Sutter, C., Ramser, J., Niederacher, D., and Horv\u00e1th, J. (2022). Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancers, 14.","DOI":"10.3390\/cancers14133292"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Klijn","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (2001). Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 358, 1389\u20131399.","DOI":"10.1016\/S0140-6736(01)06524-2"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.21.00999","article-title":"Management of Women with Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2","volume":"39","author":"Robson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10549-023-06946-8","article-title":"The association between age at breast cancer diagnosis and prevalence of pathogenic variants","volume":"199","author":"Daly","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102159","DOI":"10.1016\/j.eclinm.2023.102159","article-title":"Influence of family history on penetrance of hereditary cancers in a population setting","volume":"64","author":"Jackson","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer","volume":"297","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2014.59.0463","article-title":"Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1\/2 Mutation Carriers","volume":"33","author":"Vos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_37","unstructured":"Post, T. (2023). Factors that modify breast cancer risk in women. UpToDate, UpToDate."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/bcr1365","article-title":"BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families","volume":"8","author":"Antoniou","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","article-title":"Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis","volume":"7","author":"Kratz","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CCO.0000000000000423","article-title":"Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: Temporal phases of Li-Fraumeni syndrome","volume":"30","author":"Amadou","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated with Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.gim.2021.08.016","article-title":"Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants","volume":"24","author":"Li","year":"2022","journal-title":"Genet. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr2919","article-title":"Rare variants in the ATM gene and risk of breast cancer","volume":"13","author":"Goldgar","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajhg.2024.02.002","article-title":"Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain","volume":"111","author":"Hu","year":"2024","journal-title":"Am. J. Human Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","article-title":"Large-scale genotyping identifies 41 new loci associated with breast cancer risk","volume":"45","author":"Michailidou","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41698-024-00741-4","article-title":"Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing","volume":"8","author":"Pal","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hakkaart, C., Pearson, J.F., Marquart, L., Dennis, J., Wiggins, G.A.R., Barnes, D.R., Robinson, B.A., Mace, P.D., Aittom\u00e4ki, K., and Andrulis, I.L. (2022). Copy number variants as modifiers of breast cancer risk for BRCA1\/BRCA2 pathogenic variant carriers. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03978-6"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/ejhg.2016.203","article-title":"Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers","volume":"25","author":"Walker","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Thakur, C., Qiu, Y., Fu, Y., Bi, Z., Zhang, W., Ji, H., and Chen, F. (2022). Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.971288"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Park, H.L. (2020). Epigenetic Biomarkers for Environmental Exposures and Personalized Breast Cancer Prevention. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17041181"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Infante, M., Arranz-Ledo, M., Lastra, E., Abella, L.E., Ferreira, R., Orozco, M., Hern\u00e1ndez, L., Mart\u00ednez, N., and Dur\u00e1n, M. (2022). Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911499"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2019.11.019","article-title":"Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis","volume":"156","author":"Rahimi","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-016-0768-3","article-title":"Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women","volume":"18","author":"Rebbeck","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdq460","article-title":"Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population","volume":"22","author":"Lavie","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Giacomazzi, J., Selistre, S., Duarte, J., Ribeiro, J.P., Vieira, P.J.C., de Souza Macedo, G., Rossi, C., Czepielewski, M., Netto, C.B.O., and Hainaut, P. (2013). TP53p.R337H is a conditional cancer-predisposing mutation: Further evidence from a homozygous patient. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-187"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ejhg.2013.85","article-title":"CHEK2*1100delC homozygosity in the Netherlands\u2014Prevalence and risk of breast and lung cancer","volume":"22","author":"Huijts","year":"2014","journal-title":"Eur. J. Human Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2011-100380","article-title":"CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women","volume":"48","author":"Adank","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","article-title":"High risk of breast cancer in women with biallelic pathogenic variants in CHEK2","volume":"180","author":"Rainville","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"a005652","DOI":"10.1101\/mcs.a005652","article-title":"Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities","volume":"6","author":"Kamal","year":"2020","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","article-title":"The Fanconi Anemia Pathway in Cancer","volume":"3","author":"Niraj","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1947","article-title":"Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer","volume":"39","author":"Reid","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.breast.2023.01.003","article-title":"Polygenic risk scores and breast cancer risk prediction","volume":"67","author":"Roberts","year":"2023","journal-title":"Breast"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41588-020-0609-2","article-title":"Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses","volume":"52","author":"Zhang","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-016-0759-4","article-title":"The genetics of breast cancer risk in the post-genome era: Thoughts on study design to move past BRCA and towards clinical relevance","volume":"18","author":"Skol","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S13139","article-title":"The genetics of breast cancer: Risk factors for disease","volume":"4","author":"Collins","year":"2011","journal-title":"Appl. Clin. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"djw302","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e208501","DOI":"10.1001\/jamanetworkopen.2020.8501","article-title":"Association of a Polygenic Risk Score with Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes","volume":"3","author":"Gallagher","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: A comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"djv042","DOI":"10.1093\/jnci\/djv042","article-title":"Twenty-five years of breast cancer risk models and their applications","volume":"107","author":"Gail","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.2217\/fon-2023-0365","article-title":"Advances in breast cancer risk modeling: Integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment","volume":"19","author":"Pesapane","year":"2023","journal-title":"Future Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zhang, X., Rice, M., Tworoger, S.S., Rosner, B.A., Eliassen, A.H., Tamimi, R.M., Joshi, A.D., Lindstrom, S., Qian, J., and Colditz, G.A. (2018). Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002644"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10549-016-3953-2","article-title":"Breast cancer risk prediction using a clinical risk model and polygenic risk score","volume":"159","author":"Shieh","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_82","unstructured":"(2024, November 27). The Ask2Me.Org. Available online: https:\/\/ask2me.org\/."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.22.00833","article-title":"BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers","volume":"41","author":"Sun","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-021-01399-7","article-title":"Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry","volume":"23","author":"Brook","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4247-z","article-title":"Breast cancer risk models: A comprehensive overview of existing models, validation, and clinical applications","volume":"164","author":"Braun","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10897-018-0238-4","article-title":"A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations","volume":"27","author":"Braun","year":"2018","journal-title":"J. Genet. Couns."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41416-019-0476-8","article-title":"A systematic review and quality assessment of individualised breast cancer risk prediction models","volume":"121","author":"Louro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jbi\/wbab001","article-title":"Assessing Risk of Breast Cancer: A Review of Risk Prediction Models","volume":"3","author":"Kim","year":"2021","journal-title":"J. Breast Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mbuya-Bienge, C., Pashayan, N., Kazemali, C.D., Lapointe, J., Simard, J., and Nabi, H. (2023). A Systematic Review and Critical Assessment of Breast Cancer Risk Prediction Tools Incorporating a Polygenic Risk Score for the General Population. Cancers, 15.","DOI":"10.3390\/cancers15225380"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jmedgenet-2012-101415","article-title":"Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1\/2 mutation carrier probabilities: A study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium","volume":"50","author":"Fischer","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1214\/19-STS729","article-title":"Risk Models for Breast Cancer and Their Validation","volume":"35","author":"Brentnall","year":"2020","journal-title":"Stat. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e180174","DOI":"10.1001\/jamaoncol.2018.0174","article-title":"Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density","volume":"4","author":"Brentnall","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/JCO.2016.69.8944","article-title":"Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials","volume":"35","author":"Cuzick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jbi\/wbz006","article-title":"A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model","volume":"1","author":"Brentnall","year":"2019","journal-title":"J. Breast Imaging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13058-015-0653-5","article-title":"Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort","volume":"17","author":"Brentnall","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"109019","DOI":"10.1016\/j.ejrad.2020.109019","article-title":"Impact of adding breast density to breast cancer risk models: A systematic review","volume":"127","author":"Vilmun","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: Updates to cancer incidences, tumour pathology and web interface","volume":"110","author":"Lee","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2013.280","article-title":"Cancer chemoprevention: A rapidly evolving field","volume":"109","author":"Steward","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_100","first-page":"19","article-title":"Cancer chemoprevention: Current state of the art","volume":"7","author":"Iyer","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e00520","DOI":"10.34172\/jrhs.2021.57","article-title":"Factors for the Primary Prevention of Breast Cancer: A Meta-Analysis of Prospective Cohort Studies","volume":"21","author":"Poorolajal","year":"2021","journal-title":"J. Res. Health Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-023-01636-1","article-title":"Modifiable risk factors in women at high risk of breast cancer: A systematic review","volume":"25","author":"Cohen","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13053-020-0137-1","article-title":"Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1\/2 pathogenic Germline gene variants: Systematic review","volume":"18","author":"Coletta","year":"2020","journal-title":"Hered. Cancer Clin. Pract."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10689-011-9437-y","article-title":"Serum levels of IGF-I and BRCA penetrance: A case control study in breast cancer families","volume":"10","author":"Pasanisi","year":"2011","journal-title":"Fam. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Bruno, E., Oliverio, A., Paradiso, A.V., Daniele, A., Tommasi, S., Tufaro, A., Terribile, D.A., Magno, S., Filippone, A., and Venturelli, E. (2020). A Mediterranean Dietary Intervention in Female Carriers of BRCA Mutations: Results from an Italian Prospective Randomized Controlled Trial. Cancers, 12.","DOI":"10.3390\/cancers12123732"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kiechle, M., Dukatz, R., Yahiaoui-Doktor, M., Berling, A., Basrai, M., Staiger, V., Niederberger, U., Marter, N., Lammert, J., and Grill, S. (2017). Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers\u2014An interventional randomized controlled multicenter trial (LIBRE-1). BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3732-4"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr3138","article-title":"Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"14","author":"Kotsopoulos","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2019.05.005","article-title":"Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome","volume":"116","author":"Khincha","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2019.5780","article-title":"Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-023-06991-3","article-title":"Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation","volume":"201","author":"Kotsopoulos","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kotsopoulos, J. (2018). BRCA Mutations and Breast Cancer Prevention. Cancers, 10.","DOI":"10.3390\/cancers10120524"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41416-023-02293-z","article-title":"Side effects of low-dose tamoxifen: Results from a six-armed randomised controlled trial in healthy women","volume":"129","author":"Gabrielson","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41416-021-01392-z","article-title":"Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: Findings from the UK Biobank","volume":"125","author":"Reeves","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_119","unstructured":"(2024, November 27). Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT), Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2020.38.15_suppl.1534","article-title":"Five year letrozole versus placebo in BRCA1\/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial","volume":"38","author":"Pujol","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-022-06688-z","article-title":"Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers","volume":"196","author":"Goutsouliak","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","article-title":"Hereditary diffuse gastric cancer: Updated clinical practice guidelines","volume":"21","author":"Blair","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk","volume":"33","author":"King","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"v60","DOI":"10.1093\/annonc\/mdz240.010","article-title":"Neoadjuvant olaparib monotherapy in primary triple negative breast cancer","volume":"30","author":"Eikesdal","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","article-title":"Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer","volume":"3","author":"Spring","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-022-00411-3","article-title":"PARP inhibition in breast cancer: Progress made and future hopes","volume":"8","author":"Tung","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.breast.2021.05.009","article-title":"Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis","volume":"59","author":"Chang","year":"2021","journal-title":"Breast"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","article-title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","volume":"161","author":"Kotsopoulos","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/cr.2016.69","article-title":"RANKL\/RANK control Brca1 mutation","volume":"26","author":"Sigl","year":"2016","journal-title":"Cell Res."},{"key":"ref_135","unstructured":"Garber, J.E. (2024, November 27). BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04711109?cond=Breast%20Cancer&term=prevention%20and%20hereditary&page=2&rank=19."},{"key":"ref_136","unstructured":"Kiechle, M. (2024, November 27). Prospective Randomized Multicenter Trial to Assess the Efficacy of a Structured Physical Exercise Training and Mediterranean Diet in Women with BRCA1\/2 Mutations, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02516540?cond=Breast%20Cancer&term=prevention%20and%20hereditary&page=2&rank=14."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5152\/ejbh.2019.4651","article-title":"What the Surgeons Should Know About the Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers","volume":"15","author":"Franceschini","year":"2019","journal-title":"Eur. J. Breast Health"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"ref_139","first-page":"Cd012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Stuursma, A., van der Vegt, B., Jansen, L., Berger, L.P.V., Mourits, M.J.E., and de Bock, G.H. (2023). The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant. Cancers, 15.","DOI":"10.3390\/cancers15072095"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Gaba, F., Blyuss, O., Tan, A., Munblit, D., Oxley, S., Khan, K., Legood, R., and Manchanda, R. (2023). Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15051625"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral Oophorectomy and All-Cause Mortality in Women with BRCA1 and BRCA2 Sequence Variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_143","first-page":"Cd002748","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1245\/s10434-022-11913-6","article-title":"Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers","volume":"29","author":"Corso","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41416-023-02503-8","article-title":"Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: An international analysis","volume":"130","author":"Metcalfe","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41436-021-01151-8","article-title":"Management of individuals with germline variants in PALB2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Tischkowitz","year":"2021","journal-title":"Genet. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Teoh, V., Tasoulis, M.K., and Gui, G. (2020). Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation. Cancers, 12.","DOI":"10.3390\/cancers12010140"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e2031","DOI":"10.1002\/mgg3.2031","article-title":"Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes","volume":"10","author":"Comeaux","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2022.11.036","article-title":"EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy","volume":"181","author":"Schmidt","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","article-title":"The impact of coding germline variants on contralateral breast cancer risk and survival","volume":"110","author":"Morra","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"ref_154","unstructured":"Metcalfe, K., Lubinski, J., and Soukupov\u00e1, J. (2023, January 5\u20139). Surgical treatment of women with breast cancer and a BRCA1 mutation: An international analysis of the impact of bilateral mastectomy on survival. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_155","unstructured":"National Institute for Health and Care Excellence (2019). Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer [Internet], National Institute for Health and Care Excellence."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000530584","article-title":"St. Gallen\/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer\u2014A Brief Summary of the Consensus Discussion","volume":"18","author":"Balic","year":"2023","journal-title":"Breast Care"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"127","DOI":"10.15430\/JCP.2020.25.3.127","article-title":"An Overview of Cancer Prevention: Chemoprevention and Immunoprevention","volume":"25","author":"Gu","year":"2020","journal-title":"J. Cancer Prev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cam4.3898","article-title":"A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?","volume":"10","author":"Cai","year":"2021","journal-title":"Cancer Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","article-title":"MRI Surveillance and Breast Cancer Mortality in Women with BRCA1 and BRCA2 Sequence Variations","volume":"10","author":"Lubinski","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-18-0200","article-title":"Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers","volume":"25","author":"Guindalini","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast Cancer Screening Strategies for Women with ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.34326","article-title":"The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome","volume":"128","author":"Hoxhaj","year":"2022","journal-title":"Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"102522","DOI":"10.1016\/j.ctrv.2023.102522","article-title":"Germline TP53 pathogenic variants and breast cancer: A narrative review","volume":"114","author":"Blondeaux","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","article-title":"Li-Fraumeni syndrome: Cancer risk assessment and clinical management","volume":"11","author":"McBride","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"538","DOI":"10.31128\/AJGP-04-21-5954","article-title":"Benefits and burdens of risk management for young people with inherited cancer: A focus on Li-Fraumeni syndrome","volume":"50","author":"Keogh","year":"2021","journal-title":"Aust. J. General. Pract."},{"key":"ref_166","unstructured":"Cancer Institute NSW (2024, November 27). TP53 (Li-Fraumeni)\u2014Risk Management (Adult). eviQ [Updated 13 May 2022]. Available online: https:\/\/www.eviq.org.au\/cancer-genetics\/adult\/risk-management\/749-tp53-li-fraumeni-risk-management-adult#evidence-for-risk-management-guidelines."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jmedgenet-2020-106876","article-title":"UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants","volume":"58","author":"Hanson","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Human Genet."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, X., Dong, L., Huang, X., Zhao, H., Li, J., Huang, S., Yuan, P., Wang, W., and Wang, J. (2021). The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients with Germline Pathogenic Variants in Cancer Predisposition Genes. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.710156"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1148\/radiol.2021201948","article-title":"Contrast-enhanced Mammography: State of the Art","volume":"299","author":"Jochelson","year":"2021","journal-title":"Radiology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00330-015-3803-3","article-title":"Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: Results from the Malm\u00f6 Breast Tomosynthesis Screening Trial, a population-based study","volume":"26","author":"Andersson","year":"2016","journal-title":"Eur. Radiol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/1\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:27:38Z","timestamp":1759919258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/1\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":171,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["genes16010082"],"URL":"https:\/\/doi.org\/10.3390\/genes16010082","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}